Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins Leukemia (2013) 27, 241-245; doi:10.1038/leu.2012.163
Tumor-derived cell lines provide valuable models to assess disease characteristics but require careful assessment with regard to their representation of parental disease, and here genetic imprints from recent advances in genomic sequencing of primary tumor cells may prove highly relevant. In the rare B-cell malignancy Hairy Cell Leukemia (HCL), a number of cell lines have been generated, but evidence linking cell lines to primary tumor Accepted article preview online 18 June 2012; advance online publication, 13 July 2012 Letters to the Editor remains incomplete. These include Hair-M, 1 HCLL-7876, 2 EH, 3 Eskol, 4 HC-1 (ref. 5) and HCLv-07, 6 examined to date for 'tumor'-associated CD20 phosphorylation, 7 interferon-a oncogene regulation, 8 CD11c gene expression 9 and HCL cell adhesion and migration. 10 Here we have assessed these HCL cell lines further by examining the phenotype in more detail, by comparing B-cell receptor (BCR) function and by evaluating the BRAF mutation. The BRAF V600E mutation is present near universally in typical HCL. [11] [12] [13] However, a few cases lack this signature mutation, associated with tumor use of the IGHV4-34 gene, 14 and in a solitary HCL case expressing CD5. 15 In HCL variant (HCLv) disease, the absence of the BRAF V600E mutation is a consistent feature. [12] [13] [14] We evaluated six HCL cell lines, each expressing a single pre-or post-switched isotype for diagnostic markers, comparing them with primary tumors expressing a single isotype (s-HCL) (Figure 1 ). Of these cell lines, HCLv-07 is known to be derived from HCLv. 6 Under the WHO (World Health Organization) (2008) guidelines, HCL immunophenotype includes bright CD11c expression with CD103, CD25, CD123 and Annexin A1 (ANXA1) coexpression. 16 ANXA1 is regarded as the most specific tumor marker for HCL, as it is absent on other B-cell lymphomas [16] [17] [18] and is negative in HCLv to provide a highly relevant marker to segregate these two forms of disease. 16, 17 Immunostaining for tartrate-resistant acid phosphatase (TRAP) is also a diagnostic tool for HCL. 16 CD5 expression in HCL, although infrequent (5/133; 4% of cases 19 ), has led to CD5 þ HCL being described as 'atypical' disease. 15 CD5 expression in HCLv is also rare (1/72 cases [20] [21] [22] ), and CD25 and CD123 expression is usually negative, 16 but this is not an absolute finding. 20 Notably, four of the cell lines (HCLL-7876 ¼ Eskol4HC-14Hair-M) were positive for ANXA1 expression by western blot analysis for the 38-kDa-size protein (Figures 1a-c) , using the antibody 'Purified Mouse anti-Annexin I', clone 29/Annexin I 17 (BD Transduction Laboratories, Oxford, UK). Positive controls for ANXA1 expression included four primary s-HCL tumor samples (s-HCL1/14/15/17) and two healthy PBMNC (peripheral blood mononuclear cells) preparations (non-B-cell positive). ANXA1 expression was also gauged by immunostaining of acetone-fixed cytospin preparations, using the same antibody with anti-mouse immunoglobulin (Ig)-peroxidase and diaminobenzidine substrate for detection, and hematoxylin staining for nuclei. The level of ANXA1 expression in the HCLL-7876 HCL cell line was lower than that seen in primary s-HCL tumor cells by both western blot analysis ( Figure 1b ) and immunostaining ( Figure 1c) . However, ANXA1 expression was a consistent feature of the bulk of cells in the selected HCLL-7876 cell line, with ANXA1 staining both nuclear and cytoplasmic protein as found in primary s-HCL cells ( Figure 1c ) and confirming western blot data. Separate studies also report convergence of results for detection of ANXA1 with western blots and immunostaining. 23, 24 It is noteworthy that in extensive immunohistochemical staining for ANXA1 and other diagnostic markers in HCL cases showing weak or focal staining were scored as positive. 18 These criteria affirm ANXA1 expression in the HCLL-7876 cell line, and indicate that its expression in the other three cell lines (Eskol, HC-1 and Hair-M) can also be considered positive. Two cell lines (EH and HCLv-07) were clearly negative for ANXA1 (Figures 1a and b) by western blot analysis, an expected phenotype for HCLv-07. ANXA1 immunostaining in the EH cell line confirmed its absence ( Figure 1c ). As EH is CD5 þ (Figures 1a and d) , it is unclear from these data whether it associates with 'atypical' HCL 15 or the rare CD5 þ HCLv cases. [20] [21] [22] Other HCL phenotypic markers were assessed by flow cytometry, and relative levels of expression scored using well-defined mean fluorescence intensity ranges from replicate assays (Supplementary Table 1 ). All HCL cell lines expressed CD11c and were negative for CD27 (Figure 1a ), a known feature in HCL. 25 Of the four HCL cell lines shown to express ANXA1, each also expressed CD25 and CD123 at mid to high levels ( þ þ to þ þ þ ), at least 2-fold higher than in the HCLv-07 cell line (Figures 1a and d ). CD103 expression in 3/4 of the ANXA1 þ cell lines was at mid to strong levels ( þ þ to þ þ þ þ ), although in HCLL-7876 its expression was relatively low (Figures 1a and d) . Expression of CD103, CD25 and CD123 in HCLv-07 was low ( þ ), as expected (Figures 1a and d) . 16 , also expresses TRAP, 3 whereas HCLv-07 is negative for TRAP activity. 6 This again tends to suggest that EH may be closer to CD5
þ 'atypical' HCL. The use of the IGHV gene was also evaluated in each of the cell lines, revealing somatic mutations in each tumor-derived gene (Figure 1a) , resembling the main immunogenetic finding in HCL. None expressed the IGHV4-34 gene (Figure 1a) . 14 The dual aspect of mutated IGHV genes yet absence of CD27 expression, the classical marker for normal germinal center-derived memory B cells, has raised the question of an unusual cell of origin in HCL, for which our recent report of normal IgM þ B cells that lack CD27 and carry a low level of mutations in IGHV genes may be relevant. 26 We also examined BCR function in tumor cells selected by CD19, CD11c
Hi and CD103 expression, using anti-surface immunoglobulin (sIg) isotype-specific stimuli with goat F(ab') 2 (Figure 1f ), as measured using the irreversible pan-caspase inhibitor ApoStat (R&D Systems, Abingdon, UK) or Apo2.7 (Beckman Coulter, High Wycombe, UK). In our recent study in a cohort of 10 HCL cases, we showed that specific anti-BCR signals in primary tumor cells initiate Ca 2 þ flux and induce ERK1/2 phosphorylation, leading to levels of apoptosis significantly beyond that observed spontaneously ex vivo.
27 Taken together, comparable BCR function in cell lines and primary HCL tumors were indicative of common behavior, but did not distinguish between the variant HCLv-07 and other cell lines.
To probe these cell lines further, we evaluated the BRAF mutation (V600E) that has recently been established as a signature molecular lesion in typical HCL. [11] [12] [13] We analyzed genomic DNA and mRNA from HCL cell lines and s-HCL cases by PCR amplification and DNA sequencing, with each sample analyzed in duplicate. Design of PCR primers amplified either a 256-bp DNA fragment incorporating exon 15, where the BRAF (V600E) mutation resides (BRAFDNA FWD 5 0 -TACCTAAACTCTTCATAATGCTTGC-3 0 , BRAFDNA REV 5 0 -GTAACTCAGCAGCATCTCAGGG-3 0 ), 11 or a 532-bp fragment spanning exons 13-16 for mRNA analysis by RT-PCR (BRAFmRNA FWD 5 0 -GTGACAGCACCTACACCTCAGCAGTTAC-3 0 , BRAFmRNA REV 5 0 -GGTCCCTGTTGTTGATGTTTGAATAAGG-3 0 ). Strikingly, the HCL-associated BRAF mutation was absent in each of the four ANXA1 þ cell lines (Eskol, Hair-M, HC-1 and HCLL-7876; Figures 2a and b) , which differs from typical HCL. In contrast, Letters to the Editor the characteristic BRAF T1860A (V600E) mutation was readily observed in 4/4 primary s-HCLs (Figures 2a and b) . The lack of the BRAF mutation in HCLv-07 is to be expected of HCLv origins. 14 
Its absence in the CD5
þ EH cell line tends to further suggest an association with CD5 þ 'atypical' HCL, although thus far only a single such case has been evaluated for this mutation. þ 'atypical' HCL disease, 15 although its origin from the rare CD5 þ HCLv disease cannot be ruled out, and finally the BRAF mutation negative HCLv-07 recapitulates the expected features of HCLv tumors. [12] [13] [14] Importantly, these observations exemplify the relevance of molecular findings from next-generation sequencing of tumor genomes to integrate models of disease. 2 However, even in high-quality cytogenetic preparations, G-banding analysis suffers from an inherent limit in resolution, such that rearrangements o5-10 megabases in size, particularly those involving uniformly pale G-banded regions, may be impossible to be detected. Molecular genetic approaches such as reverse transcriptase-PCR (RT-PCR) have demonstrated that a small percentage of apparently normal karyotypes may harbor cryptic versions of known recurrent translocations, which are generated by submicroscopic insertions or more complex rearrangements. 3 The cryptic NUP98-NSD1 fusion involves the nucleoporin gene 98 (NUP98) on chromosome 11p15 and the non-homeobox gene NSD1 in chromosomal band 5q35. NUP98 encodes a 98-kDa protein of the nuclear pore complex, and is known to fuse to at least 21 different fusion gene partners in chromosomal rearrangements of various hematopoietic disorders.
4 NSD1 contains two distinct nuclear receptor interaction domains, as well as a SET domain and multiple PHD fingers, both of which are frequently found in transcriptional regulators and may be involved in chromatin remodeling. 5, 6 NSD1 is thought to function as both a transcriptional coactivator and a corepressor. The NUP98-NSD1 fusion gene has been shown to induce AML in vivo, which sustains self-renewal of myeloid stem cells in vitro, and enforces expression of the HOXA7, HOXA9, HOXA10 and MEIS1 proto-oncogenes. 7 Recently, Hollink et al. 8 published a study on NUP98-NSD1 in 293 pediatric and 808 adult cytogenetically normal AML (CN-AML) cases. The NUP98-NSD1 fusion gene has been described in this single study with a frequency of 16.1% in pediatric and 2.3% in adult AML patients with distinct characteristics (for example, mutual exclusiveness with NPM1) and dismal prognosis. The aim of our study was to further investigate the frequency and clinical relevance of the NUP98-NSD1 fusion transcript in 378 adult cases of de novo NPM1 unmutated (NPM1wt) CN-AML. Furthermore, we screened 64 adult AML cases with cytogenetic aberrations involving chromosomes 5 and 11 for the presence of NUP98-NSD1 fusion gene. In addition, we aimed at evaluating this fusion transcript as a target for quantitative RT-PCR (qRT-PCR)-based minimal residual disease (MRD) monitoring. The study design adhered to the tenets of the Declaration of Helsinki and was approved by our institutional review board before its initiation. NUP98-NSD1 fusion transcript analysis was performed on either bone marrow or peripheral blood samples. Presence of 
